Halfords Delivers Consistent and Convenient Shopping Experiences with Juniper Networks’ AI-driven Wired and Wireless Access Solutions
Juniper Networks ®, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Halfords, the UK’s leading provider of motoring and cycling products and services selected Juniper’s AI-driven wired and wireless access solutions in its stores, garages and offices to serve as a flexible foundation for its business growth and operational efficiency. The 125-year-old company has invested heavily to accelerate its digital transformation, leveraging the benefits of Mist AI and the cloud to create better commercial services and a unified, omnichannel retail experience for its customers. Halfords has reduced network-related trouble tickets by 100 percent and has seen a 35 percent improvement in uptime in the garages and stores where the deployment has been completed.
The Juniper® AI-driven network provides an agile digital foundation for Halfords’ continued success and drives a more consistent and convenient customer experience across locations and channels. It can tailor communications to Halfords Motoring Club members when they come to the store. The new network provides employees details about products such as child seats, cycle racks and roof racks, so they can have informed conversations with customers and sell with greater confidence.
Halfords pivoted during the pandemic, with strong growth in online sales and the addition of contactless tactics such as click-and-collect in its parking lots. Its innovative mobile field service software was key to delivering 70,000 services safely and efficiently per week for more than four years at its auto centers and customers’ homes. Many pandemic-motivated shopping behaviors are now permanent, requiring an IT infrastructure that is flexible and scalable enough to support changing customer demands.
As shoppers return to stores to test drive an electric bike, get an oil change or replace worn tires, for example, reliable wired and wireless connectivity is essential for both workers and shoppers alike. Halfords had an aging in-store network that was increasingly a roadblock to sales and service due to inconsistent performance and difficult troubleshooting, which resulted in poor user and operator experiences. To address this, the retailer is now deploying a Juniper wired and wireless network across its retail stores, auto centers and offices. Mist AI works in conjunction with Juniper Access Points to deliver scalable and reliable Wi-Fi 6 and virtual Bluetooth® LE services to Halfords’ staff and customer smartphones, point-of-sale devices, in-store video displays and other connected devices. Juniper EX Series switches provide high-performance, secure access to wired devices with AI-driven automation and insights for easy provisioning, troubleshooting and operations. Marvis™, the industry’s only virtual network assistant driven by Mist AI, provides proactive actions for easy fault identification and self-driving network operations for fast and proactive correction. Juniper is a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure for the 3rd year in a row, positioned highest on the ability to execute axis and furthest to the right on the completeness of vision axis.
Halfords plan to transform its network further with the modernization of its WAN, which connects its 1400+ stores, auto centers and mobile service vans. To achieve this, they are also planning to deploy Juniper’s AI-driven SD-WAN solution, which leverages the same cloud and Mist AI engine as their new wired and wireless network. By deploying a full-stack Juniper solution, Halfords can achieve superlative insight into end-to-end user experiences and the superior automation from client-to-cloud.
Halfords worked with ConnectedID, a Juniper partner, to create the optimal network architecture, working on the design, validation and testing to ensure that the Juniper solutions met Halfords’ strategic goals.
Supporting Quotes:
“The network is a utility. It is a big part of our digital transformation journey, and we needed a very intelligent, secure network with next-generation capabilities. Juniper is a disruptor in the industry. The network user experience that it offers far exceeds anything else in the market. The ease of operations and self-healing capabilities of Juniper’s technology, along with the user experience metrics it delivers for Halfords, are outstanding.”
- Neil Holden, Chief Information Officer, Halfords
“Smart retailers like Halfords are leveraging AI technologies to ensure customers’ shopping experiences are positive at every touchpoint. Halfords has invested in Juniper’s AI solutions to build a more detailed picture of its customers to keep up with changing consumer behavior. Mist AI helps Halfords optimize user experiences and simplify IT operations with automated network assurance and the proactive problem detection and resolution. Users and devices have predictable connectivity and the number of network-related trouble tickets have dropped by 100 percent.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Halfords: Success Story
- 2022 Gartner Magic Quadrant for Enterprise Wired and Wireless LAN Infrastructure: View Report
- Blog: When it Comes to Wired & Wireless Access, Juniper Mist is in the Driver’s Seat
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Category – AI
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005100/en/
Contact information
Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
